Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsNeighborhood Health Plan Icotyde Prior Auth | Open…
    Ask Trek AI about this page
    CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

    Icotyde (icotrokinra) Coverage Criteria for Moderate to Severe Plaque Psoriasis

    Customize your policy alerts

    Sign up for all Neighborhood Health Plan of Rhode Island policy alerts

    Know when Neighborhood Health Plan of Rhode Island releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Medicaid prior authorization and coverage of Icotyde for moderate to severe plaque psoriasis in eligible adults and pediatric patients. Coverage requires documentation of medical necessity, specified prior treatment history, safety screening, and response to therapy.

    Policy Summary
    PayerNeighborhood Health Plan of Rhode Island
    PolicyIcotyde (icotrokinra) coverage criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNovember 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit the member's chart or medical record documenting medical necessity and satisfy the applicable indication and safety criteria before requesting coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 monthsInitial and continuation authorization period
    12+ yearsMinimum age for covered plaque psoriasis treatment
    ≥40 kgMinimum weight for pediatric patients
    1 tablet/day

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Icotyde 200 mg quantity limit
    Plaque psoriasisCovered FDA-approved indication
    All other indicationsExperimental or investigational and not covered

    Coverage Criteria

    Initial therapy - moderate to severe plaque psoriasis

    Initial authorization of 6 months may be granted for moderate to severe plaque psoriasis when all of the following are met.

    Global and indication-specific requirements

    • Safety and documentation requirements

      • Required documentation and safety conditions: The provider submits the member's chart or medical record documenting medical necessity; baseline disease severity is assessed with an objective measure or tool; Icotyde is not used concomitantly with an injectable biologic response modifier or another oral non-biologic agent; the member is free of any clinically important active infection; the member will not receive live vaccines during therapy; and the member has been screened for latent tuberculosis before treatment with ongoing TB monitoring.
    • Eligibility and specialist involvement

      • Age, weight, and prescriber: The member is at least 12 years of age, weighs at least 40 kg, and Icotyde is prescribed by or in consultation with a dermatologist.Age >=12 years; weight >=40 kg
    • Disease severity or topical-treatment criterion

      • ONE of

        • The affected body surface area is at least 10%.BSA >=10%
        • Crucial body areas are affected, including the face, hands, feet, genitals, or scalp.
        • The member has had an inadequate treatment response to topical therapy, including corticosteroids, calcineurin inhibitors, vitamin D analogs, or retinoids.
    • Prior conventional treatment or first-line rationale

      • ONE of

        • The member has had an inadequate response, intolerance, or contraindication to at least a 3-month trial of a conventional oral agent for plaque psoriasis, such as methotrexate, cyclosporine, or acitretin.Trial duration >=3 months
        • The member has had an inadequate response, intolerance, or contraindication to at least a 3-month trial of phototherapy, such as UVB or PUVA.Trial duration >=3 months
        • Clinical rationale has been provided indicating that the member's disease severity warrants a biologic DMARD as first-line therapy.
    • Required advanced-therapy history

      • Age-based adalimumab and ustekinumab requirement

        • If the member is 18 years of age or older, the member has had an inadequate response, intolerance, or contraindication to at least a 3-month trial of adalimumab and a 6-month trial of an ustekinumab biosimilar at maximum tolerated doses.Adult adalimumab >=3 months; ustekinumab biosimilar >=6 months at maximum tolerated doses
        • If the member is under 18 years of age, the member has had an inadequate response, intolerance, or contraindication to at least a 6-month trial of an ustekinumab biosimilar at maximum tolerated doses.Ustekinumab biosimilar >=6 months at maximum tolerated doses
      • Additional required therapy: The member has also had an inadequate response, intolerance, or contraindication to at least a 6-month trial of one of the following: Cosentyx (secukinumab), Ilumya (tildrakizumab), Tremfya (guselkumab), or Otezla (apremilast).Trial duration >=6 months

    Continuation therapy

    Continuation authorization of 6 months may be granted for all members, including new members, when the following is met.

    Continuation response

    • Positive clinical response: The requested medication is being used for moderate to severe plaque psoriasis and documentation demonstrates a positive clinical response, evidenced by low disease activity, such as a reduction in affected BSA from baseline, or improvement from baseline in signs and symptoms including itching, redness, flaking, scaling, burning, cracking, or pain.Authorization period: 6 months

    Indications other than the listed FDA-approved uses for moderate to severe plaque psoriasis are considered experimental or investigational and are not a covered benefit.

    Clinical Thresholds and Treatment Durations

    Affected body surface area
    Minimum affected BSAAt least 10%
    Applies whenBSA is used to establish moderate to severe plaque psoriasis disease severity
    DocumentationSubmit documentation of the affected body surface area
    Pediatric weight
    Minimum pediatric weightAt least 40 kg
    Minimum age12 years of age or older
    Treatment eligibilityCandidates for systemic therapy or phototherapy

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Icotyde. Submit the member's chart or medical record documenting medical necessity and all criteria applicable to the requested indication; coverage applies only when approval criteria are met and no therapy exclusions apply.

    • Include objective baseline disease-severity assessment and supporting clinical documentation with the request.
    Documentation Required

    Six-Month Initial Approval

    Initial authorization may be granted for 6 months for moderate to severe plaque psoriasis when all applicable clinical, severity, prior-treatment, and safety criteria are documented.

    • Member is at least 12 years old and weighs at least 40 kg.
    • Icotyde is prescribed by or in consultation with a dermatologist.
    • Document BSA of at least 10%, involvement of crucial body areas, or inadequate response to topical therapy.

    Policy Background

    Icotyde (icotrokinra) is covered for moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy, and in pediatric patients 12 years of age and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy.

    Definitions

    BSA
    TermBSA
    DefinitionBody surface area affected by psoriasis
    Policy thresholdAt least 10% BSA when this criterion is used to establish disease severity
    PsO
    TermPsO
    DefinitionPlaque psoriasis
    Covered severityModerate to severe plaque psoriasis

    Initial Icotyde Approval

    Initial Icotyde approval

    Initial authorization of 6 months may be granted when all applicable global safety, psoriasis-severity, specialist, and prior-treatment requirements are met.

    Initial Icotyde requirements

    • Global safety and documentation requirements: The provider submits the member's chart or medical record documenting medical necessity; baseline disease severity is assessed with an objective measure or tool; Icotyde is not used concomitantly with an injectable biologic response modifier or another oral non-biologic agent; the member is free of any clinically important active infection; the member will not receive live vaccines during therapy; and the member has been screened for latent tuberculosis before treatment with ongoing TB monitoring.
    • Eligibility and specialist involvement: The member is at least 12 years of age, weighs at least 40 kg, and Icotyde is prescribed by or in consultation with a dermatologist.Age >=12 years; weight >=40 kg
    • Disease severity or topical-treatment criterion

    Continuation of Icotyde

    Continuation of Icotyde

    Authorization of 6 months may be granted for all members, including new members, when response documentation is submitted.

    Positive clinical response

    • The member is using Icotyde for moderate to severe plaque psoriasis and documentation demonstrates a positive clinical response, evidenced by low disease activity, such as a reduction in affected BSA from baseline, or improvement from baseline in signs and symptoms including itching, redness, flaking, scaling, burning, cracking, or pain.6-month authorization

      Applies to all members, including new members.

    Required Treatment Sequence

    Member groupRequired prior therapiesMinimum trial durationRequired outcome
    Adults (18 years or older)Adalimumab; ustekinumab biosimilar at maximum tolerated doses; and one of Cosentyx (secukinumab), Ilumya (tildrakizumab), Tremfya (guselkumab), or Otezla (apremilast)Adalimumab: at least 3 months; ustekinumab biosimilar: at least 6 months; additional listed therapy: at least 6 monthsInadequate response, intolerance, or contraindication
    Members under 18 yearsUstekinumab biosimilar at maximum tolerated doses; and one of Cosentyx (secukinumab), Ilumya (tildrakizumab), Tremfya (guselkumab), or Otezla (apremilast)Ustekinumab biosimilar: at least 6 months; additional listed therapy: at least 6 monthsInadequate response, intolerance, or contraindication
    StepRequired prior therapyMinimum trialRequirement before Icotyde
    2Conventional oral psoriasis agent (for example, methotrexate, cyclosporine, or acitretin) OR phototherapy (for example, UVB or PUVA)At least 3 monthsInadequate response, intolerance, or contraindication, unless clinical rationale supports biologic DMARD therapy as first-line treatment

    Icotyde Quantity Limit

    Icotyde 200 mg tablet
    DrugIcotyde 200 mg tablet
    Maximum covered quantity1 tablet per day
    Excess quantityRequests exceeding 1 tablet per day exceed the stated quantity limit

    Ustekinumab Biosimilar Requirement

    Billing Rule

    Document the ustekinumab biosimilar trial

    Document the required 6-month trial of an ustekinumab biosimilar at maximum tolerated doses before requesting Icotyde. Adults additionally require an inadequate response, intolerance, or contraindication to at least a 3-month trial of adalimumab.

    • Members under 18 require the 6-month ustekinumab biosimilar trial.
    • Adults require both the ustekinumab biosimilar and adalimumab trials.
    • Include evidence of inadequate response, intolerance, or contraindication and the applicable treatment duration.
    Policy Summary
    PayerNeighborhood Health Plan of Rhode Island
    PolicyIcotyde (icotrokinra) coverage criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNovember 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit the member's chart or medical record documenting medical necessity and satisfy the applicable indication and safety criteria before requesting coverage.
    SourceLink
    On This Page
    Coverage CriteriaClinical Thresholds and Treatment DurationsAuthorization, Documentation, and Denial RisksPolicy BackgroundDefinitionsInitial Icotyde ApprovalContinuation of IcotydeRequired Treatment SequenceIcotyde Quantity LimitUstekinumab Biosimilar Requirement
    Conventional oral agent trial
    Minimum trial durationAt least 3 months
    Required outcomeInadequate response, intolerance, or contraindication
    ExamplesMethotrexate, cyclosporine, or acitretin
    Phototherapy trial
    Minimum trial durationAt least 3 months
    Required outcomeInadequate response, intolerance, or contraindication
    ExamplesUVB or PUVA
    Adult adalimumab trial
    Minimum trial durationAt least 3 months
    Applies toMembers 18 years of age or older
    Required outcomeInadequate response, intolerance, or contraindication
    Ustekinumab biosimilar trial
    Minimum trial durationAt least 6 months
    Dose conditionAt maximum tolerated doses
    Required outcomeInadequate response, intolerance, or contraindication
    Additional advanced-therapy trial
    Minimum trial durationAt least 6 months
    Required outcomeInadequate response, intolerance, or contraindication
    Eligible therapiesCosentyx, Ilumya, Tremfya, or Otezla
  1. Document required prior advanced-therapy and conventional-therapy or phototherapy history, unless a qualifying first-line biologic-DMARD rationale is provided.
  2. Documentation Required

    Six-Month Continuation Approval

    Continuation authorization may be granted for 6 months, including for new members, when documentation shows a positive clinical response to Icotyde for moderate to severe plaque psoriasis.

    • Document low disease activity, such as a reduction in BSA affected from baseline, or improvement from baseline in signs and symptoms including itching, redness, flaking, scaling, burning, cracking, or pain.
    Step Therapy

    Required Prior Advanced Therapies

    Before adult treatment, document inadequate response, intolerance, or contraindication to the required advanced therapies at maximum tolerated doses. Pediatric members must meet the applicable ustekinumab biosimilar requirement.

    • Adults 18 years and older: at least a 3-month trial of adalimumab and a 6-month trial of an ustekinumab biosimilar.
    • Members younger than 18 years: at least a 6-month trial of an ustekinumab biosimilar.
    • All members: also document an inadequate response, intolerance, or contraindication to at least a 6-month trial of Cosentyx, Ilumya, Tremfya, or Otezla.
    Step Therapy

    Conventional Therapy or Phototherapy

    Document an inadequate response, intolerance, or contraindication to at least a 3-month trial of a conventional oral agent for psoriasis, such as methotrexate, cyclosporine, or acitretin, or to at least a 3-month trial of phototherapy, such as UVB or PUVA. A clinical rationale may instead support biologic DMARD use as first-line therapy when disease severity warrants it.

    • The qualifying conventional-therapy or phototherapy history must be included in the medical record submission.
    Documentation Required

    Medical Record and Safety Documentation

    Submit the medical record supporting medical necessity, objective baseline severity, and treatment safety. Icotyde must not be used with prohibited concomitant therapies, and specified infection, vaccination, and tuberculosis precautions must be addressed.

    • Document an objective baseline disease-severity assessment.
    • Do not use concomitantly with an injectable biologic response modifier, including TNF inhibitors or IL inhibitors, or another oral non-biologic agent.
    • Member must be free of clinically important active infection, including clinically important localized infection.
    • Member must not receive live vaccines during therapy.
    • Screen for latent tuberculosis before initiation and provide ongoing TB monitoring during treatment.
    Documentation Required

    Psoriasis Severity and Specialist Documentation

    For the moderate to severe plaque psoriasis indication, document the member's age, weight, specialist involvement, and disease severity in the submitted record.

    • Member must be 12 years of age or older.
    • Weight must be at least 40 kg.
    • Icotyde must be prescribed by or in consultation with a dermatologist.
    • Document at least one: BSA affected of 10% or more; crucial body-area involvement such as the face, hands, feet, genitals, or scalp; or inadequate response to topical corticosteroids, calcineurin inhibitors, vitamin D analogs, or retinoids.
    Step Therapy

    Prior Treatment History

    Document inadequate response, intolerance, or contraindication to each required prior therapy, including the applicable duration and maximum tolerated dosing where specified.

    • Adults: adalimumab for at least 3 months and an ustekinumab biosimilar for at least 6 months at maximum tolerated doses.
    • Members under 18: an ustekinumab biosimilar for at least 6 months at maximum tolerated doses.
    • Additionally, one of Cosentyx, Ilumya, Tremfya, or Otezla must have been tried for at least 6 months.
    • Document the applicable conventional oral-agent or phototherapy trial for at least 3 months, unless qualifying clinical rationale supports biologic DMARD first-line treatment.
    Documentation Required

    Continuation Response Documentation

    For renewal, submit evidence that the member is responding positively to Icotyde for moderate to severe plaque psoriasis. Authorization may be continued for 6 months, including for new members, when the response is documented.

    • Show low disease activity, such as reduced BSA from baseline, or improvement in baseline itching, redness, flaking, scaling, burning, cracking, or pain.
    Denial Risk

    Noncovered Indication

    Icotyde is covered for moderate to severe plaque psoriasis in qualifying adults and pediatric patients 12 years of age and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. All other indications are experimental or investigational and are not covered.

    • Do not submit Icotyde for indications outside the covered moderate to severe plaque psoriasis population as a covered benefit.
    Denial Risk

    Safety and Concomitant Therapy Restrictions

    Requests may be denied when safety requirements are not met or when Icotyde is prescribed with prohibited concomitant therapy.

    • Do not combine Icotyde with injectable biologic response modifiers, including TNF inhibitors or IL inhibitors, or other oral non-biologic agents.
    • Do not treat during clinically important active infection or administer live vaccines during therapy.
    • Complete latent-TB screening before initiation and ongoing monitoring during treatment.
    Denial Risk

    Incomplete Clinical Criteria

    Requests may be denied when the submitted record does not establish the applicable clinical criteria. Ensure the request includes complete severity, specialist, weight, prior-treatment, medical-necessity, and safety documentation.

    • Missing age or weight eligibility, dermatologist involvement, objective baseline severity, BSA or crucial-area involvement, or topical-treatment history may support denial.
    • Missing required advanced-therapy, conventional oral-agent, or phototherapy history—or documentation of intolerance, contraindication, or inadequate response—may support denial.
    • Missing safety screening, prohibited-concomitant-therapy attestations, or other required medical-record evidence may support denial.
    Billing Rule

    Quantity Limit Exceeded

    The quantity limit is one Icotyde 200 mg tablet per day. Requests exceeding this limit may be denied unless an applicable plan exception is approved.

    • Do not request more than 1 Icotyde 200 mg tablet daily.
    DMARD
    TermDMARD
    DefinitionDisease-modifying antirheumatic drug
    Policy contextA biologic DMARD may be used as first-line therapy when clinical rationale supports it
    • The affected body surface area is at least 10%.BSA >=10%
    • Crucial body areas are affected, including the face, hands, feet, genitals, or scalp.
    • The member has had an inadequate treatment response to topical therapy, including corticosteroids, calcineurin inhibitors, vitamin D analogs, or retinoids.
  3. Prior conventional treatment or first-line rationale

    • The member has had an inadequate response, intolerance, or contraindication to at least a 3-month trial of a conventional oral agent for plaque psoriasis, such as methotrexate, cyclosporine, or acitretin.Trial duration >=3 months
    • The member has had an inadequate response, intolerance, or contraindication to at least a 3-month trial of phototherapy, such as UVB or PUVA.Trial duration >=3 months
    • Clinical rationale has been provided indicating that the member's disease severity warrants a biologic DMARD as first-line therapy.
  4. Required advanced-therapy history

    • Age-based adalimumab and ustekinumab requirement

      • If the member is 18 years of age or older, the member has had an inadequate response, intolerance, or contraindication to at least a 3-month trial of adalimumab and a 6-month trial of an ustekinumab biosimilar at maximum tolerated doses.Adult adalimumab >=3 months; ustekinumab biosimilar >=6 months at maximum tolerated doses
      • If the member is under 18 years of age, the member has had an inadequate response, intolerance, or contraindication to at least a 6-month trial of an ustekinumab biosimilar at maximum tolerated doses.Ustekinumab biosimilar >=6 months at maximum tolerated doses
    • Additional required therapy: The member has also had an inadequate response, intolerance, or contraindication to at least a 6-month trial of one of the following: Cosentyx (secukinumab), Ilumya (tildrakizumab), Tremfya (guselkumab), or Otezla (apremilast).Trial duration >=6 months